NCT07751159 Radiation Therapy Approaches for People With Prostate Cancer
| NCT ID | NCT07751159 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Prostate Cancer Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 126 participants |
| Start Date | 2026-07-31 |
| Primary Completion | 2030-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 126 participants in total. It began in 2026-07-31 with a primary completion date of 2030-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to explore the best ways of giving radiation therapy to balance cancer control and treatment side effects.
Eligibility Criteria
Inclusion Criteria: * Non-metastatic prostate cancer. * Classified as unfavorable intermediate-, high-, or very high-risk prostate cancer according to NCCN risk stratification guidelines. (Note: cT3a or T3b by MRI or PSMA PET allowed) * Considered by the treating radiation oncologist as a suitable candidate for both HDR brachytherapy boost and SBRT Exclusion Criteria: * None
Contact & Investigator
Daniel Gorovets, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07751159 clinical trial?
This trial is open to participants of all sexes, studying Prostate Cancer Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07751159 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07751159 currently recruiting?
Yes, NCT07751159 is actively recruiting participants. Contact the research team at gorovetd@mskcc.org for enrollment information.
Where is the NCT07751159 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT07751159 clinical trial?
NCT07751159 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Daniel Gorovets, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 126 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.